current
recommend
treatment
chronic
hepat
c
viru
hcv
infect
combin
pegyl
alpha
interferon
ifn
ribavirin
given
week
viral
host
factor
may
contribut
phenomenon
patient
chronic
hepat
c
respond
well
ifn
therapi
other
specif
viral
factor
genotyp
high
hcv
rna
level
associ
higher
incid
resist
ifn
therapi
also
host
factor
old
age
advanc
fibrosi
long
durat
diseas
host
genet
factor
advers
influenc
respons
ifn
treatment
host
genet
factor
mediat
vigor
immun
respons
host
control
differ
product
intracellular
antivir
protein
cytokin
differ
may
attribut
singl
nucleotid
polymorph
snp
human
genom
significantli
influenc
progress
chronic
hcv
infect
respons
therapi
biolog
activ
ifn
therapi
mediat
induct
intracellular
antivir
protein
oligoadenyl
synthetas
oa
dsrna
activ
protein
kinas
pkr
mxa
protein
oa
protein
select
activ
sever
virus
requir
doubl
strand
ds
rna
structur
viral
genom
becom
activ
activ
enzym
catalyz
polymer
adenosin
triphosph
atp
link
oligoadenyl
turn
bind
activ
latent
ribonucleas
l
rnasel
degrad
viral
rna
inhibit
protein
synthesi
system
may
also
involv
growth
apoptosi
synthetas
gene
compris
gene
famili
gene
locat
human
chromosom
encod
isoform
import
clear
viral
infect
demonstr
differ
studi
human
report
basal
activ
vari
among
individu
associ
suscept
diabet
mellitu
type
whose
pathogenesi
thought
involv
enteroviru
infect
furthermor
previou
analysi
human
respons
yellow
fever
vaccin
reveal
highli
signific
correl
basal
enzym
activ
activ
measur
day
vaccin
actual
hcv
patient
sever
find
report
regard
hcv
core
protein
specif
activ
gene
promot
manner
differ
human
hepatocyt
deriv
cell
line
ii
activ
core
protein
enhanc
cell
treat
alpha
interferon
iii
induc
level
lower
patient
patient
thu
genet
variant
affect
activ
could
import
determin
susceptibilityresist
antivir
treatment
diseas
progress
although
critic
antivir
interact
sequenc
strictli
conserv
eight
snp
exon
snp
intron
three
promot
one
region
utr
gene
report
genet
marker
strongli
associ
enzym
activ
strongest
genet
associ
activ
occur
exon
sa
gene
sequenc
ag
requir
normal
splice
site
g
allel
acceptor
site
retain
splice
site
associ
high
enzym
activ
wherea
allel
aa
acceptor
site
ablat
splice
site
associ
low
enzym
activ
ghosh
et
al
report
basal
activ
higher
person
carri
g
allel
allel
find
suggest
strong
genet
control
basal
activ
genet
polymorph
exon
sa
make
excel
candid
human
gene
significantli
influenc
host
suscept
viral
infect
affect
diseas
progress
respons
ifn
therapi
patient
hepat
c
hepat
b
viral
infect
present
studi
investig
egyptian
hcv
genotyp
infect
patient
healthi
individu
control
determin
genet
snp
exon
sa
human
gene
associ
reduc
respons
ifn
base
therapi
seventi
patient
proven
chronic
hepat
c
receiv
pegyl
ifn
ribavirin
treatment
healthi
control
neg
hcv
ab
rna
well
hepat
b
surfac
antigen
hbsag
enrol
studi
subject
egyptian
unrel
inform
consent
obtain
subject
collect
blood
sampl
hcv
patient
posit
antibodi
serum
hcv
rna
revers
chain
reaction
patient
infect
hcv
genotyp
detect
hcv
innogenet
gent
belgium
viral
rna
quantif
perform
use
copu
amplicor
hcv
monitor
test
roch
pleasanton
ca
usa
ifn
treatment
clinic
perform
depart
tropic
medicin
kasr
el
aini
hospit
cairo
univers
prior
start
ifn
therapi
patient
persist
elev
serum
alanin
aminotransferas
alt
level
least
month
none
evid
metabol
liver
diseas
autoimmun
hepat
thyroid
activ
schistosomiasi
infect
pretreat
liver
biopsi
carri
histopatholog
examin
assess
stage
fibrosi
accord
metavir
score
patient
treat
interferon
ribavirin
combin
therapi
week
receiv
linear
pegyl
peg
deriv
hansenula
polymorpha
express
system
compani
ramadan
citi
egypt
taken
week
sc
addit
oral
ribavirin
taken
daili
dose
mg
accord
bodi
weight
patient
follow
least
month
complet
therapi
sustain
virolog
respond
svr
n
defin
patient
test
neg
hcv
rna
use
nest
pcr
least
month
end
treatment
etr
combin
therapi
patient
show
svr
consid
nr
n
disappear
hcv
viremia
confirm
varieti
test
includ
use
nest
primer
deriv
highli
conserv
hcv
pcr
hcv
rna
extract
use
rna
extract
reagent
kit
hangzhou
bioer
technolog
hangzhou
china
hepat
c
viru
quantif
perform
use
fluoresc
quantit
detect
kit
hangzhou
bioer
technolog
hangzhou
china
hcv
rna
revers
transcrib
specif
fragment
amplifi
specif
primer
reaction
product
detect
use
specif
probe
probe
hangzhou
bioer
technolog
hangzhou
china
pcr
reaction
done
accord
manufactur
recommend
pcr
tube
place
real
time
pcr
detect
instrument
stratagen
la
jolla
ca
usa
blood
sampl
healthi
control
patient
undergo
ifn
base
treatment
collect
genom
dna
extract
peripher
blood
mononuclear
cell
pbmc
digest
proteinas
k
subsequ
salt
cellular
protein
use
sodium
chlorid
follow
ethanol
precipit
final
storag
requir
pair
primer
amplifi
snp
region
provid
bp
pcr
fragment
cover
exon
ag
site
design
use
input
http
optim
pcr
protocol
thermal
cycl
program
follow
pcr
amplif
carri
contain
ng
dna
mm
promega
madison
wi
usa
nm
primer
mm
dntp
promega
pcr
buffer
promega
go
taq
dna
polymeras
promega
thermal
cycl
mj
research
cycler
includ
denatur
min
follow
cycl
denatur
anneal
extens
min
cycl
follow
final
extens
step
min
primer
sequenc
follow
forward
primer
revers
primer
restrict
fragment
length
polymorph
rflp
analysi
construct
detect
ag
allel
nucleotid
exon
sa
gene
use
theoret
restrict
map
program
http
wwwnebcuttercom
identifi
restrict
endonucleas
alui
recogn
sequenc
snp
within
exon
sa
long
pcr
fragment
subject
digest
alu
promega
alui
restrict
digest
perform
pcr
product
least
h
total
volum
alui
accord
manufactur
recommend
digest
product
run
agaros
gel
stain
ethidium
bromid
observ
uv
transillumin
frequenc
exon
snp
compar
control
group
versu
chronic
hcv
patient
group
statist
differ
group
determin
test
independ
predict
factor
associ
svr
ifn
treatment
studi
use
stepwis
multinomi
logist
regress
analysi
statist
analys
perform
use
spss
statist
softwar
program
odd
ratio
confid
interv
ci
calcul
assess
rel
risk
confid
two
tail
consid
statist
signific
statist
analysi
allow
us
determin
degre
snp
influenc
outcom
hcv
infect
respons
therapi
subject
patient
control
descend
egyptian
origin
repres
governor
countri
explor
whether
clinic
patholog
biochem
virolog
paramet
associ
specif
respons
pattern
comparison
svr
nr
outlin
tabl
among
total
chronic
hcv
patient
univari
analys
factor
show
signific
differ
patient
popul
age
sex
bodi
mass
index
bmi
viral
load
hand
alpha
fetoprotein
afp
level
significantli
higher
nr
svr
patient
p
also
lower
stage
liver
fibrosi
associ
higher
probabl
achiev
svr
p
wherea
higher
stage
hepat
activ
fibrosi
higher
among
nr
patient
popul
tabl
hepat
activ
amount
inflamm
specif
intens
lesion
grade
scale
indic
mild
activ
wherea
indic
moder
sever
activ
presenc
aa
genotyp
exon
sa
indic
complet
digest
bp
pcr
product
use
alui
agct
two
fragment
bp
bp
gg
genotyp
indic
absenc
alui
site
g
polymorph
gener
indigest
sequenc
ggct
retain
intact
bp
pcr
fragment
case
heterozygos
ag
three
fragment
bp
bp
bp
appear
agaros
gel
electrophoresi
shown
figur
explor
whether
test
snp
repres
signific
genet
compon
egyptian
popul
subject
healthi
control
sex
expos
rflp
analysi
exon
sa
examin
whether
allel
associ
chronic
hcv
infect
compar
frequenc
test
snp
group
human
genotyp
control
group
gg
ga
aa
result
indic
g
allel
tend
frequent
allel
control
infect
popul
howev
control
genotyp
gg
slightli
higher
chronic
hcv
patient
vs
shown
figur
frequenc
differ
genotyp
svr
patient
show
trend
g
allel
aa
ag
gg
p
aa
genotyp
detect
svr
versu
nr
patient
shown
figur
hand
patient
aa
ga
genotyp
significantli
higher
fibrosi
score
gg
genotyp
p
shown
tabl
investig
whether
test
snp
exist
frequent
either
svr
nr
group
patient
gg
genotyp
detect
patient
ga
patient
aa
nine
patient
shown
tabl
gg
genotyp
detect
svr
group
nr
group
vs
frequenc
genotyp
allel
exon
sa
compar
svr
nr
patient
analys
allel
pool
studi
sampl
reveal
number
allel
nine
patient
aa
patient
ag
wherea
number
g
allel
patient
gg
patient
ga
nr
patient
higher
frequenc
allel
much
svr
patient
p
shown
tabl
signific
sever
host
factor
determin
respons
ifn
therapi
investig
stepwis
logist
regress
analysi
histolog
pattern
liver
fibrosi
activ
differ
oa
genotyp
exon
sa
afp
level
less
ngml
independ
significantli
influenc
outcom
ifn
therapi
tabl
order
studi
effect
singl
factor
control
effect
factor
stepwis
logist
regress
analysi
perform
hcv
patient
higher
fibrosi
stage
significantli
higher
risk
respons
low
fibrosi
stage
chanc
respons
confid
p
hand
allel
oa
exon
sa
increas
risk
respons
g
allel
confid
p
individu
infect
hcv
may
exhibit
spectrum
possibl
outcom
abl
clear
viru
natur
wherea
other
develop
persist
infect
chronic
infect
patient
minim
progress
diseas
wherea
other
develop
sever
liver
diseas
elev
transaminas
level
chronic
hepat
steatosi
liver
fibrosi
cirrhosi
host
viral
factor
thought
influenc
hcv
diseas
outcom
respons
ifn
treatment
sinc
patient
egypt
infect
hcv
genotyp
seem
applic
carri
current
studi
patient
infect
genotyp
receiv
pegyl
ifn
ribavirin
dose
mention
method
section
host
genet
factor
affect
outcom
ifn
treatment
chronic
hepat
c
investig
sever
snp
gene
lead
alter
gene
express
function
found
associ
diverg
respons
ifn
treatment
understand
patient
like
develop
persist
infect
progress
liver
diseas
respond
significantli
interferon
therapi
would
utmost
import
diseas
control
program
studi
show
specif
human
mutat
result
reduc
function
known
antivir
gene
associ
resist
interferon
therapi
hcv
infect
patient
code
compon
type
interferon
signal
system
homolog
mice
shown
previous
import
flaviviru
suscept
observ
suggest
polymorph
exon
site
gene
may
involv
determin
outcom
hcv
infect
patient
harbor
gg
genotyp
site
tend
achiev
sustain
respons
interferon
therapi
suggest
g
allel
confer
better
signal
toward
viral
clearanc
hand
clear
associ
exist
allel
contain
genotyp
ga
aa
resist
interferon
therapi
respect
find
confirm
earlier
report
g
allel
acceptor
site
retain
splice
site
associ
higher
oa
enzym
activ
wherea
allel
aa
acceptor
site
ablat
splice
site
result
larger
molecular
weight
protein
lower
oa
enzym
activ
role
oa
enzym
activ
combat
viral
infect
previous
document
snp
exon
relat
develop
sever
acut
respiratori
syndrom
sar
coronaviru
infect
recent
lim
et
al
report
individu
carri
two
copi
hypofunct
variant
found
frequent
expect
among
asymptomat
symptomat
west
nile
viru
wnv
posit
individu
prove
activ
influenc
probabl
wnv
initi
infect
upon
exposur
man
knowledg
previou
report
effect
differ
genotyp
exon
splice
acceptor
site
respons
rate
hcv
infect
patient
combin
interferon
ribavirin
therapi
knapp
et
al
report
differ
genotyp
specif
snp
within
gene
associ
differenti
respons
ifn
therapi
like
associ
persist
infect
patient
moreov
li
et
al
show
relationship
snp
exon
gene
ifn
treatment
respons
okuno
et
al
solina
et
al
pawlotski
et
al
hypothes
play
greater
role
mediat
versu
persist
hcv
infect
compon
innat
immun
system
ifn
stimul
gene
role
exogen
administ
ifn
treatment
current
data
support
hypothesi
sinc
snp
allel
aa
ga
gene
slightli
overrepres
hcv
patient
compar
control
respect
find
indic
play
role
persist
hcv
infect
contrari
site
specif
snp
studi
exhibit
deleteri
effect
enzym
activ
henc
expect
dramat
influenc
ifn
mediat
signal
transduct
pathway
presum
ga
aa
genotyp
could
neg
affect
suppress
function
oa
hcv
replic
may
therefor
relat
sustain
inflamm
progress
liver
diseas
hypothesi
support
result
present
studi
hepat
fibrosi
score
higher
aa
ga
genotyp
compar
gg
genotyp
chronic
hcv
patient
posit
allel
significantli
higher
fibrosi
score
metavir
observ
patient
without
allel
aa
ga
vs
gg
p
interestingli
fibrosi
score
higher
oa
variant
includ
allel
exon
sa
gene
fashion
allel
oa
exon
sa
f
score
patient
liver
hand
signific
associ
differ
oa
genotyp
liver
activ
p
may
explain
fact
allel
encod
weak
abil
suppress
hcv
replic
compar
g
allel
code
activ
enzym
thu
presenc
allel
may
lead
higher
degre
necrosi
regener
ultim
higher
degre
fibrosi
latter
find
support
previou
result
li
et
al
found
snp
exon
associ
diseas
progress
japanes
patient
hcv
infect
gener
effect
differ
oa
genotyp
liver
diseas
progress
hcv
patient
need
studi
rel
studi
aim
identifi
human
genet
differ
influenc
progress
chronic
viral
infect
respons
interferon
recent
snp
identifi
locat
upstream
gene
encod
strongli
associ
sustain
virolog
respons
pegifn
ribavirin
patient
matsushita
et
al
show
associ
polymorph
lectin
gene
ifn
respons
japanes
patient
chronic
hepat
c
moreov
hijikata
et
al
show
snp
gt
nt
promot
region
mxa
gene
associ
respons
ifn
japanes
hcv
patient
possibl
host
protein
differ
function
may
also
associ
via
divers
mechan
respons
ifn
chronic
hcv
patient
present
multivari
analysi
result
indic
gene
polymorph
factor
influenc
antivir
activ
host
cell
viral
infect
howev
multivari
analysi
show
snp
exon
splice
acceptor
site
independ
signific
determin
outcom
ifn
therapi
odd
ratio
confid
interv
p
taken
togeth
present
data
recent
find
laboratori
role
cytomegaloviru
cmv
coinfect
well
liver
fibrosi
score
outcom
viral
respons
ifn
base
therapi
would
valuabl
compon
predict
mathemat
model
select
ideal
patient
cohort
start
cours
treatment
conclus
result
present
studi
may
clinic
pathogen
implic
suggest
snp
exon
splice
acceptor
site
repres
ad
valu
promis
marker
prognosi
diseas
progress
predict
drug
respons
patient
clinic
practic
